Senate estimates questioning on Australia's 2021 vaping regulations
Source material dated November 2022 · Agencies and guidance
Overview
This page summarises a 2022 article about questioning of the head of the Therapeutic Goods Administration at a Senate estimates hearing in November 2022. The questions concerned the prescription-based vaping rules that started on 1 October 2021. The source argued the testimony showed the rules were not working. It is the source's reading of the hearing, and the official record is the better guide to what was said.
What the source said was acknowledged
According to the source, the regulator's head accepted at the hearing that:
- youth vaping had increased sharply;
- large numbers of low-quality products were entering Australia and being sold illicitly, and could not be stopped;
- only about one per cent of registered doctors had applied to be authorised prescribers;
- fewer than one in ten adult vapers held a prescription.
The source also reported that several senators criticised the framework during the session.
The source's criticisms
The source pointed to what it saw as inconsistencies, such as the regulator's head describing the current regime as ineffective while saying the agency should be proud of its work, and denying that the rules had created the illicit market. It also noted that review points promised at three, six and twelve months had been dropped without announcement, and that a closed meeting of experts was held in September 2022 without publishing attendees.
On policy, it argued that attention to youth access had overshadowed access for adult smokers, and said further restrictions would mean less legal vaping and more smoking-related deaths.
Context and limits
The article is an opinion piece and uses sharp language about officials, which this summary does not adopt. The regulator's explanations are not set out in full, and the later rule changes in 2024 post-date the article. The figures are those the source attributed to the hearing.
Based on a 2022 opinion article.
Related summaries
- A journal critique of a national research council statement on e-cigarettes
- Criticism of a national research council's 2022 vaping guidance
- A critique of a joint health-group position statement on vaping
- A 2017 critique of a medical association submission to a federal e-cigarette inquiry